PL3597649T3 - Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2 - Google Patents
Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2Info
- Publication number
- PL3597649T3 PL3597649T3 PL19194930T PL19194930T PL3597649T3 PL 3597649 T3 PL3597649 T3 PL 3597649T3 PL 19194930 T PL19194930 T PL 19194930T PL 19194930 T PL19194930 T PL 19194930T PL 3597649 T3 PL3597649 T3 PL 3597649T3
- Authority
- PL
- Poland
- Prior art keywords
- triazolo
- pyrimidin
- compounds
- compositions containing
- containing substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983387P | 2014-04-23 | 2014-04-23 | |
| EP15721086.5A EP3134413B1 (en) | 2014-04-23 | 2015-04-22 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors |
| EP19194930.4A EP3597649B8 (en) | 2014-04-23 | 2015-04-22 | Compositions containing substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors |
| PCT/US2015/027102 WO2015164508A1 (en) | 2014-04-23 | 2015-04-22 | Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3597649T3 true PL3597649T3 (pl) | 2022-04-04 |
Family
ID=53055118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19194930T PL3597649T3 (pl) | 2014-04-23 | 2015-04-22 | Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9932345B2 (pt-PT) |
| EP (2) | EP3134413B1 (pt-PT) |
| JP (1) | JP6626449B2 (pt-PT) |
| KR (1) | KR102471058B1 (pt-PT) |
| CN (2) | CN110092788B (pt-PT) |
| AU (2) | AU2015249753B2 (pt-PT) |
| BR (1) | BR112016024713B1 (pt-PT) |
| CA (1) | CA2938294C (pt-PT) |
| DK (2) | DK3597649T3 (pt-PT) |
| ES (2) | ES2759246T3 (pt-PT) |
| HR (1) | HRP20212035T1 (pt-PT) |
| HU (1) | HUE057317T2 (pt-PT) |
| IL (2) | IL248292A (pt-PT) |
| MA (1) | MA50375A (pt-PT) |
| MX (1) | MX358004B (pt-PT) |
| NZ (1) | NZ725161A (pt-PT) |
| PL (1) | PL3597649T3 (pt-PT) |
| PT (1) | PT3597649T (pt-PT) |
| RU (1) | RU2659070C9 (pt-PT) |
| SG (1) | SG11201606216UA (pt-PT) |
| SI (1) | SI3597649T1 (pt-PT) |
| TW (1) | TWI664181B (pt-PT) |
| WO (1) | WO2015164508A1 (pt-PT) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2659070C9 (ru) | 2014-04-23 | 2018-08-24 | Дарт Нейросайенс (Кайман) Лтд. | ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 |
| CA2958966C (en) | 2014-08-28 | 2020-01-14 | Asceneuron Sa | Substituted cyclic amines as glucosidase inhibitors |
| EP3215508A1 (en) * | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors |
| MY194700A (en) * | 2015-11-02 | 2022-12-15 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound |
| CA3012624A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
| AU2017222958B2 (en) | 2016-02-25 | 2019-07-18 | Asceneuron S. A. | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| US10696668B2 (en) | 2016-02-25 | 2020-06-30 | Asceneuron Sa | Acid addition salts of piperazine derivatives |
| AU2017353315B2 (en) * | 2016-11-02 | 2021-09-16 | Janssen Pharmaceutica Nv | (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors |
| CN109923116B (zh) * | 2016-11-02 | 2022-12-06 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶衍生物 |
| MX2019005123A (es) * | 2016-11-02 | 2019-06-20 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. |
| CN110312716A (zh) * | 2016-12-16 | 2019-10-08 | 詹森药业有限公司 | 双环oga抑制剂化合物 |
| US20200157092A1 (en) * | 2017-02-27 | 2020-05-21 | Janssen Pharmaceutlca NV | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
| EP3969639A1 (en) | 2019-05-13 | 2022-03-23 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
| TW202220992A (zh) | 2020-08-05 | 2022-06-01 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2510111A1 (fr) * | 1981-07-24 | 1983-01-28 | Roussel Uclaf | Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| HU208693B (en) | 1991-02-22 | 1993-12-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them |
| US5478825A (en) | 1991-02-22 | 1995-12-26 | Egis Gyogyszergyar | 5-(substituted amino)-1,2,4-triazolo (1,5-A) pyrimidine derivatives |
| ATE526020T1 (de) | 2000-08-10 | 2011-10-15 | Cold Spring Harbor Lab | Gesteigertes kognitives training |
| US7868015B2 (en) | 2000-08-10 | 2011-01-11 | Cold Spring Harbor Laboratory | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
| US9931318B2 (en) | 2003-04-08 | 2018-04-03 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| DE10064105A1 (de) | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
| DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| FR2832711B1 (fr) * | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
| AU2003276220A1 (en) | 2002-11-13 | 2004-06-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) |
| WO2004108136A1 (en) * | 2003-06-04 | 2004-12-16 | Vernalis (Cambridge) Limited | Triazolo `1 , 5-a!pyrimidines and their use in medicine |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| EP1791543B1 (en) | 2004-09-02 | 2010-06-16 | Nycomed GmbH | Triazolophthalazines |
| ES2397080T3 (es) | 2005-01-05 | 2013-03-04 | Nycomed Gmbh | Triazoloftalazinas como agentes inhibidores de la PDE2 |
| JP5130053B2 (ja) | 2005-01-05 | 2013-01-30 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | トリアゾロフタラジン |
| US7868016B2 (en) | 2005-07-13 | 2011-01-11 | Baxter International Inc. | Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
| CN101321758A (zh) * | 2005-10-03 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | 用于治疗哮喘和慢性阻塞性肺病的新5,6－二氢吡唑并[3,4－e][1,4]二氮杂－4(1H)－酮衍生物 |
| KR100844125B1 (ko) | 2007-03-23 | 2008-07-04 | 한국화학연구원 | 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물 |
| US20090053140A1 (en) | 2007-05-15 | 2009-02-26 | Roderick Euan Milne Scott | METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA) |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| WO2010054260A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| US20100120762A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Triazine derivatives as inhibitors of phosphodiesterases |
| MY156377A (en) | 2009-03-31 | 2016-02-15 | Boehringer Ingelheim Int | 1-heterocycl-1, 5-dihydro-pyrazolo [3 , 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| EP2456440B1 (en) | 2009-07-22 | 2015-08-19 | Merck Sharp & Dohme Corp. | Quinolinone pde2 inhibitors |
| DK2835131T3 (en) * | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| CN103391941A (zh) * | 2011-02-23 | 2013-11-13 | 辉瑞大药厂 | 用于治疗神经障碍的咪唑并[5,1-f][1,2,4]三嗪类 |
| MX2013014470A (es) | 2011-06-07 | 2014-03-21 | Pfizer | Compuestos de pirazolo[3,4-d]pirimidina y su uso como inhibidores pde2 y/o inhibidores cyp3a4. |
| WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| WO2013034755A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders |
| WO2013034758A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
| US9056863B2 (en) | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| US20130116241A1 (en) * | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| CN103183675A (zh) * | 2011-12-27 | 2013-07-03 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-4抑制剂 |
| JPWO2015012328A1 (ja) * | 2013-07-24 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| RU2659070C9 (ru) | 2014-04-23 | 2018-08-24 | Дарт Нейросайенс (Кайман) Лтд. | ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 |
| EP3215508A1 (en) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors |
-
2015
- 2015-04-22 RU RU2016143387A patent/RU2659070C9/ru active
- 2015-04-22 MA MA050375A patent/MA50375A/fr unknown
- 2015-04-22 CN CN201910367854.6A patent/CN110092788B/zh active Active
- 2015-04-22 JP JP2016549758A patent/JP6626449B2/ja active Active
- 2015-04-22 HR HRP20212035TT patent/HRP20212035T1/hr unknown
- 2015-04-22 HU HUE19194930A patent/HUE057317T2/hu unknown
- 2015-04-22 BR BR112016024713-2A patent/BR112016024713B1/pt active IP Right Grant
- 2015-04-22 DK DK19194930.4T patent/DK3597649T3/da active
- 2015-04-22 WO PCT/US2015/027102 patent/WO2015164508A1/en active Application Filing
- 2015-04-22 SG SG11201606216UA patent/SG11201606216UA/en unknown
- 2015-04-22 KR KR1020167032113A patent/KR102471058B1/ko active IP Right Grant
- 2015-04-22 EP EP15721086.5A patent/EP3134413B1/en active Active
- 2015-04-22 ES ES15721086T patent/ES2759246T3/es active Active
- 2015-04-22 AU AU2015249753A patent/AU2015249753B2/en active Active
- 2015-04-22 CN CN201580030165.6A patent/CN106459062A/zh active Pending
- 2015-04-22 CA CA2938294A patent/CA2938294C/en active Active
- 2015-04-22 SI SI201531770T patent/SI3597649T1/sl unknown
- 2015-04-22 NZ NZ725161A patent/NZ725161A/en unknown
- 2015-04-22 US US15/306,069 patent/US9932345B2/en active Active
- 2015-04-22 MX MX2016013860A patent/MX358004B/es active IP Right Grant
- 2015-04-22 PL PL19194930T patent/PL3597649T3/pl unknown
- 2015-04-22 DK DK15721086.5T patent/DK3134413T3/da active
- 2015-04-22 EP EP19194930.4A patent/EP3597649B8/en active Active
- 2015-04-22 ES ES19194930T patent/ES2902806T3/es active Active
- 2015-04-22 PT PT191949304T patent/PT3597649T/pt unknown
- 2015-04-23 TW TW104113093A patent/TWI664181B/zh active
-
2016
- 2016-10-10 IL IL248292A patent/IL248292A/en active IP Right Grant
-
2017
- 2017-08-30 IL IL254224A patent/IL254224B/en active IP Right Grant
-
2018
- 2018-02-26 US US15/905,672 patent/US10501465B2/en active Active
-
2019
- 2019-11-25 US US16/694,869 patent/US11186582B2/en active Active
- 2019-12-20 AU AU2019283994A patent/AU2019283994C1/en active Active
-
2022
- 2022-06-27 US US17/850,668 patent/US20230192698A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE057317T2 (hu) | Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok | |
| HK1258905A1 (zh) | 作為ret激酶抑制劑的取代的吡唑並[1，5-a]吡啶化合物 | |
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| IL265918A (en) | Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors | |
| HK1256751A1 (zh) | [1，2，4]三唑並[1，5-a]嘧啶-7-基化合物 | |
| EP3190113A4 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| EP3107914B8 (en) | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| EP3328840A4 (en) | TRIAZOLO BICYCLIC COMPOUNDS SUBSTITUTED AS PDE2 INHIBITORS | |
| IL247947B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors | |
| EP3319966A4 (en) | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | |
| ZA201605666B (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
| IL290419B (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
| EP3313852A4 (en) | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |